Structure-based drug designing of histone deacetylase-2 inhibitors as anticancer agents
NOPR - NISCAIR Online Periodicals Repository
View Archive InfoField | Value | |
Title |
Structure-based drug designing of histone deacetylase-2 inhibitors as anticancer agents
|
|
Creator |
Bisht, Somya
Singh, Anita Subbarao, Naidu |
|
Subject |
Histone deacetylase
molecular dynamics 4LY1 ADME property |
|
Description |
976-988
Histone deacetylase 2 (HDAC-2) in tumor development and carcinogenesis is a promising therapeutic target for cancer treatment. HDAC-2 belongs to class I histone deacetylase and acts as a transcriptional repressor through the deacetylation of lysine residues present at the N-terminal tail of histone proteins (H2A, H2B, H3, and H4). They are overexpressed in various solid tumors like cutaneous T cell lymphoma, colorectal cancer, prostate cancer, lung cancer, breast cancer, gastric cancer, liver cancer, and medulloblastoma. Hence, targeting HDAC-2 could be a rewarding strategy to combat cancer. The goal of the research is to design, develop, and identify molecules through docking, Ligplot, ADMET properties, and molecular dynamic studies. The compound CHEMBL4087539 has been observed to be a top scoring inhibitor against HDAC-2. The molecular dynamics simulation shows the convergence of ligand protein interaction. In the 100 ns, the ligand strongly interacts with HDAC-2. Furthermore, the ADME studies show the suitability of predicted inhibitor as a drug like molecule. |
|
Date |
2022-09-19T10:09:59Z
2022-09-19T10:09:59Z 2022-09 |
|
Type |
Article
|
|
Identifier |
2583-1321 (Online); 0019-5103 (Print)
http://nopr.niscpr.res.in/handle/123456789/60507 https://doi.org/10.56042/ijc.v61i9.60668 |
|
Language |
en
|
|
Publisher |
NIScPR-CSIR,India
|
|
Source |
IJC Vol.61(09) [Sep 2022]
|
|